{
    "thread": {
        "uuid": "6bf6a5725d6186af5b0b2e4f8edf84a574c64cac",
        "url": "https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19",
        "site_full": "www.marketbeat.com",
        "site": "marketbeat.com",
        "site_section": "https://www.marketbeat.com/rss.ashx?type=headlines",
        "site_categories": [
            "investing",
            "financial_news",
            "finance",
            "stocks"
        ],
        "section_title": "MarketBeat News Feed",
        "title": "Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of Stock",
        "title_full": "Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of Stock",
        "published": "2024-12-20T02:25:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "https://www.marketbeat.com/logos/avidity-biosciences-inc-logo-1200x675.jpg?v=20221208150659",
        "performance_score": 0,
        "domain_rank": 9023,
        "domain_rank_updated": "2024-12-16T23:00:00.000+02:00",
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "6bf6a5725d6186af5b0b2e4f8edf84a574c64cac",
    "url": "https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "MarketBeat",
    "published": "2024-12-20T02:25:00.000+02:00",
    "title": "Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of Stock",
    "text": "Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of Stock Written by MarketBeat December 19, 2024 Share Link copied to clipboard. Avidity Biosciences, Inc. ( NASDAQ:RNA - Get Free Report ) insider W. Michael Flanagan sold 12,742 shares of Avidity Biosciences stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $32.66, for a total value of $416,153.72. Following the transaction, the insider now directly owns 72,647 shares in the company, valued at $2,372,651.02. The trade was a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link .\nGet Avidity Biosciences alerts: Sign Up This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now? W. Michael Flanagan also recently made the following trade(s): On Wednesday, December 11th, W. Michael Flanagan sold 24,000 shares of Avidity Biosciences stock. The shares were sold at an average price of $35.77, for a total value of $858,480.00. Avidity Biosciences Stock Performance\nShares of NASDAQ RNA traded up $0.35 during trading on Thursday, hitting $31.05. 1,949,315 shares of the company traded hands, compared to its average volume of 1,310,250. The business's fifty day moving average is $42.93 and its 200 day moving average is $42.19. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of -10.78 and a beta of 0.89. Avidity Biosciences, Inc. has a fifty-two week low of $8.37 and a fifty-two week high of $56.00.\nAd Porter & Company First JFK… next Elon? Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger. I share with you in this special investigative documentary. Avidity Biosciences ( NASDAQ:RNA - Get Free Report ) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.14. Avidity Biosciences had a negative return on equity of 27.66% and a negative net margin of 2,772.45%. The business had revenue of $2.34 million for the quarter, compared to the consensus estimate of $7.09 million. On average, analysts predict that Avidity Biosciences, Inc. will post -2.89 EPS for the current year. Analysts Set New Price Targets\nSeveral analysts recently commented on the company. TD Cowen upped their target price on Avidity Biosciences from $56.00 to $78.00 and gave the company a \"buy\" rating in a report on Monday, October 21st. Evercore ISI decreased their price objective on shares of Avidity Biosciences from $54.00 to $53.00 and set an \"outperform\" rating for the company in a research report on Monday, August 26th. The Goldman Sachs Group assumed coverage on shares of Avidity Biosciences in a research report on Tuesday, September 24th. They set a \"buy\" rating and a $59.00 price target on the stock. Chardan Capital reissued a \"buy\" rating and issued a $65.00 price objective on shares of Avidity Biosciences in a research report on Wednesday, November 13th. Finally, Barclays assumed coverage on Avidity Biosciences in a research report on Wednesday, August 28th. They set an \"overweight\" rating and a $63.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of \"Buy\" and an average price target of $63.60.\nCheck Out Our Latest Stock Report on RNA Hedge Funds Weigh In On Avidity Biosciences\nA number of large investors have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Avidity Biosciences by 4.3% in the 3rd quarter. FMR LLC now owns 16,848,776 shares of the biotechnology company's stock worth $773,864,000 after acquiring an additional 689,729 shares during the last quarter. Wellington Management Group LLP increased its holdings in Avidity Biosciences by 84.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,030,949 shares of the biotechnology company's stock worth $322,931,000 after purchasing an additional 3,228,923 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Avidity Biosciences by 11.7% in the second quarter. Avoro Capital Advisors LLC now owns 6,505,000 shares of the biotechnology company's stock worth $265,729,000 after purchasing an additional 680,000 shares during the last quarter. RA Capital Management L.P. lifted its holdings in shares of Avidity Biosciences by 16.7% in the third quarter. RA Capital Management L.P. now owns 6,300,408 shares of the biotechnology company's stock valued at $289,378,000 after purchasing an additional 900,000 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Avidity Biosciences by 33.9% during the third quarter. Janus Henderson Group PLC now owns 4,896,166 shares of the biotechnology company's stock valued at $224,774,000 after buying an additional 1,239,323 shares during the last quarter. About Avidity Biosciences ( Get Free Report )\nAvidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Read More Five stocks we like better than Avidity Biosciences REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today Micron Stock Under $100: Seize the AI-Driven Upside Energy and Oil Stocks Explained AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025 Top Biotech Stocks: Exploring Innovation Opportunities SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside\nThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.\n→ WARNING: “Buffett Indicator” flashing for first time in 50 years (From Behind the Markets) (Ad) Should you invest $1,000 in Avidity Biosciences right now? Before you consider Avidity Biosciences, you'll want to hear this.\nMarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avidity Biosciences wasn't on the list.\nWhile Avidity Biosciences currently has a \"Buy\" rating among analysts, top-rated analysts believe these five stocks are better buys.\nView The Five Stocks Here\nThese 7 Stocks Will Be Magnificent in 2025 Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.\nGet This Free Report Like this article? Share it with a colleague. Link copied to clipboard.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
        "Economy, Business and Finance",
        "Social Issue",
        "Health"
    ],
    "topics": [
        "Economy, Business and Finance->financial service",
        "Health->health organisation"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "webz_reporter": false,
    "external_links": [
        "https://www.facebook.com/sharer/sharer.php?u=https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "http://www.sec.gov/Archives/edgar/data/1599901/000159990124000204/xslF345X05/wk-form4_1734650099.xml",
        "https://www.americanconsumernews.net/scripts/standalone/viewcount.ashx?type=i&id=647998&domain=marketbeat.com&referrer=",
        "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://twitter.com/intent/tweet?text=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20%24RNA%20%23RNA%20https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://www.linkedin.com/cws/share?mini=true&url=https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://www.insidertrades.com/avidity-biosciences-inc-stock/w-michael-flanagan/",
        "https://twitter.com/intent/tweet?text=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://www.american",
        "https://twitter.com/intent/tweet?text=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20%24RNA%20%23RNA%20https://marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20https://marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://www.insidertrades.com/avidity-biosciences-inc-stock/w-michael-flanagan",
        "https://american",
        "https://www.linkedin.com/cws/share?mini=true&url=https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19",
        "https://www.facebook.com/sharer/sharer.php?u=https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19",
        "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19",
        "https://americanconsumernews.net/scripts/standalone/viewcount.ashx?type=i&id=647998&domain=marketbeat.com&referrer=",
        "https://www.facebook.com/sharer/sharer.php",
        "https://facebook.com/sharer/sharer.php?u=https://marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://twitter.com/intent/tweet?text=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20https://marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://linkedin.com/cws/share?mini=true&url=https://marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19/",
        "https://www.linkedin.com/cws/share",
        "https://www.americanconsumernews.net/scripts/standalone/viewcount.ashx",
        "https://api.stocktwits.com/widgets/share",
        "https://insidertrades.com/avidity-biosciences-inc-stock/w-michael-flanagan/",
        "https://twitter.com/intent/tweet?text=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19",
        "http://sec.gov/Archives/edgar/data/1599901/000159990124000204/xslF345X05/wk-form4_1734650099.xml",
        "https://twitter.com/intent/tweet",
        "https://twitter.com/intent/tweet?text=Insider+Selling%3a+Avidity+Biosciences%2c+Inc.+(NASDAQ%3aRNA)+Insider+Sells+12%2c742+Shares+of+Stock%20%24RNA%20%23RNA%20https://www.marketbeat.com/instant-alerts/insider-selling-avidity-biosciences-inc-nasdaqrna-insider-sells-12742-shares-of-stock-2024-12-19"
    ],
    "external_images": [],
    "entities": {
        "persons": [
            {
                "name": "W. Michael Flanagan",
                "sentiment": "none"
            }
        ],
        "organizations": [
            {
                "name": "Avidity Biosciences, Inc.",
                "sentiment": "none"
            },
            {
                "name": "SEC",
                "sentiment": "none"
            }
        ],
        "locations": []
    },
    "syndication": {
        "syndicated": false,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-12-20T02:43:06.866+02:00",
    "updated": "2024-12-20T02:43:06.866+02:00"
}